{
    "clinical_study": {
        "@rank": "63765", 
        "acronym": "PK", 
        "arm_group": {
            "arm_group_label": "DCB Arm", 
            "arm_group_type": "Experimental", 
            "description": "Treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)"
        }, 
        "brief_summary": {
            "textblock": "To describe the pharmacokinetics of paclitaxel in the blood delivered from a paclitaxel\n      coated percutaneous angioplasty balloon catheter as a result of treatment of de novo or\n      restenotic lesion(s), occluded/stenotic or re-occluded/restenotic lesion(s)."
        }, 
        "brief_title": "Drug-coated Angioplasty Balloons for Subjects With Constriction or Blockage in the Leg Arteries, Specifically the Superficial Femoral or Popliteal Arteries: A Pharmacokinetic Study", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral Artery Disease", 
        "condition_browse": {
            "mesh_term": "Peripheral Arterial Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or non-pregnant female greater than or equal to 18 years of age.\n\n          -  Subjects with symptomatic leg ischemia, requiring treatment of the Superficial\n             Femoral Artery (SFA) or popliteal artery.\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating females.\n\n          -  Known intolerance to study medications, paclitaxel or contrast agents that in the\n             opinion of the investigator cannot be adequately pre-treated."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01912937", 
            "org_study_id": "TP-1363"
        }, 
        "intervention": {
            "arm_group_label": "DCB Arm", 
            "description": "Treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)", 
            "intervention_name": "Treatment with the CVI Drug-coated Balloon (DCB)", 
            "intervention_type": "Device"
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Paclitaxel", 
            "Percutaneous Transluminal Angioplasty", 
            "Balloon Catheter", 
            "Pharmacokinetic", 
            "Peripheral Artery Disease", 
            "PAD"
        ], 
        "lastchanged_date": "July 29, 2013", 
        "location": {
            "contact": {
                "last_name": "Andrew Holden, MD", 
                "phone": "+ 64 9 307 4949"
            }, 
            "facility": {
                "address": {
                    "city": "Auckland", 
                    "country": "New Zealand"
                }, 
                "name": "Auckland City Hospital"
            }, 
            "investigator": {
                "last_name": "Andrew Holden, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "New Zealand"
        }, 
        "number_of_arms": "1", 
        "official_title": "Prospective, Non-Randomized, Single-Arm, Multi-Center, Pharmacokinetic Study for the Treatment of Subjects Presenting With De Novo Occluded/Stenotic or Re-occluded/Restenotic Lesions of the Superficial Femoral or Popliteal Arteries Using a Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "New Zealand: Health and Disability Ethics Committees"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Measurement of  paclitaxel concentration in the circulating blood immediately after last balloon deployment, 1, 4, 24 hours,  7, 14, 30, 60 days and 6 months (if applicable) post-procedure.", 
                "measure": "Paclitaxel Levels", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }, 
            {
                "description": "Freedom from device and procedure-related death through 30 days post-procedure; and freedom from target limb major amputation and clinically-driven target lesion revascularization through 12 months post-procedure.", 
                "measure": "Freedom from Events as a Safety Measure (Composite)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01912937"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Measurements of Pharmacokinetics variables: Cmax, Tmax, AUC", 
            "safety_issue": "No", 
            "time_frame": "(0-t) and half-life"
        }, 
        "source": "Covidien", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Covidien", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}